


Survey: Impact of COVID-19 Pandemic on Rare Disease Patients in Canada

Question	
<p>1. At this time, to the best of your knowledge, what is the most likely impact of COVID-19 on (adequate) supply of your company's drugs to Canadian patients? If the answer varies by drug, please provide either specific drug information or respond in general across all drugs.</p>	<p>We are closely monitoring the impact of COVID-19 on our supply chain and as of now, we have not seen any disruption or impact to our business. We are working to ensure continued access of our medicines and vaccines to patients across Canada. We consistently and diligently monitor the supply of our medicines for preparedness and contingency planning to help ensure products are available for our patients. Furthermore, business continuity plans at our manufacturing sites have been invoked to ensure there is no disruption to supply. As of today, all our manufacturing sites are running at high capacity under a Pfizer-wide pandemic preparedness plan.</p> <p>In addition, we have identified several medicines used globally that are most relevant in today's situation for hospitals and affected patients. We are developing specific risk plans for these medicines that include but are not limited to intensive monitoring of demand and shifting production plans to support higher demand and safety stocks.</p> <p>We have implemented measures to protect our inventories and ensure supply continuity for the many essential medicines required by Canadian hospitals and patients. These measures include providing wholesalers with 1.5 times their normal inventory levels in order to bring more products closer to patients.</p> <p>However, we are also implementing the use of ordering restrictions for products distributed to our direct and indirect customers. This firm but necessary approach has been taken to ensure our products remain available and continue to be distributed throughout the network as equitably as possible during this critical time.</p>
<p>2. If interruption or shortage in drug supply were anticipated or took place, where could Canadian patients find information about the situation and any plans for addressing or mitigating the impact? Is there a website, information line, or contact</p>	<p>As always, the best resource to learn about drug shortages in Canada is www.DrugShortagesCanada.ca.</p> <p>We also communicate weekly with HCPs, wholesalers and Group Purchasing Organizations on the status of our product supply.</p>

	person?	
3.	This question addresses any clinical trials that your company has at this time that includes Canadian sites or Canadian patients in other countries. At this time, to the best of your knowledge, have you experienced or do you anticipate any interruptions, delays, or modifications in the conduct of these trials due to COVID-19? Please describe any modifications or other adjustments.	<p>To avoid adding to the demands on the healthcare system during this unprecedented time, as of March 24, we are pausing for three weeks the recruitment portion only of our new and ongoing global interventional clinical studies. We are taking this action in the interest of public health, so that our clinical site partners and we can concentrate on caring for patients in our ongoing clinical trials, who are our most important responsibility.</p> <p>There are some exceptions to our recruitment pause. We will continue to work to recruit studies where patients have life-threatening conditions and they have few or no other therapeutic options. This includes study C3391001 - Duchenne Muscular Dystrophy Gene Therapy.</p>
4.	To the best of your knowledge, are there any clinical trials that will not take place or will be delayed as a result of COVID-19? Please describe.	We will review this decision in three weeks and provide another update then. We expect over time to resume recruitment and new study starts on a country-by-country basis.
5.	Where can patients find information about any increased risk of getting COVID-19 or increased impact of COVID-19 due to any medications provided by your company?	Any relevant information for patients and the general public would be posted on Pfizer.ca as needed.
6.	To the best of your knowledge, are there any changes in patient support programs that are anticipated or planned, related to issues due to COVID-19? Please describe.	We are working to ensure continued access of our medicines to patients across Canada, and that includes ensuring continuity of our patient support program services.
7.	How can patients or patient organizations find updated information about your company's policies, plans, or actions related to COVID-19? How will you communicate with patients or patient groups?	Any relevant information for patients and the general public would be posted on Pfizer.ca as needed. We will continue to communicate with patient groups directly through Pfizer Canada's dedicated Patient Engagement Leads.
8.	Is there any other information that you wish to communicate share at this time?	

